Last checked at 19 Jun 2017 16:29
Issued: Monday 19 June 2017, London UK - LSE
GSK confirms start date for Luke Miels
GSK has reached an agreement with AstraZeneca that Luke Miels will commence his appointment as President, Global Pharmaceuticals, GSK on 4 September 2017.
GSK enquiries: | |||
UK Media enquiries: | Simon Steel | +44 (0) 20 8047 5502 | (London) |
David Mawdsley | +44 (0) 20 8047 5502 | (London) | |
US Media enquiries: | Sarah Alspach | +1 202 715 1048 | (Washington, DC) |
Sarah Spencer | +1 215 751 3335 | (Philadelphia) | |
Analyst/Investor enquiries: | Sarah Elton-Farr | +44 (0) 20 8047 5194 | (London) |
Tom Curry | + 1 215 751 5419 | (Philadelphia) | |
Gary Davies | +44 (0) 20 8047 5503 | (London) | |
James Dodwell | +44 (0) 20 8047 2406 | (London) | |
Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) |
GSK cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016.
| |||||||||
Registered in England & Wales: No. 3888792 |
| ||||||||
| |||||||||
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS |
| ||||||||